作者
Edward B Garon, Matthew D Hellmann, Naiyer A Rizvi, Enric Carcereny, Natasha B Leighl, Myung-Ju Ahn, Joseph Paul Eder, Ani S Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew Gubens, Suresh S Ramalingam, Enriqueta Felip, Jonathan W Goldman, Cathie Scalzo, Erin Jensen, Debra A Kush, Rina Hui
发表日期
2019/10/10
期刊
Journal of Clinical Oncology
卷号
37
期号
28
页码范围
2518
出版商
American Society of Clinical Oncology
简介
PURPOSE
Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for patients with NSCLC treated with pembrolizumab monotherapy.
学术搜索中的文章
EB Garon, MD Hellmann, NA Rizvi, E Carcereny… - Journal of Clinical Oncology, 2019